Company profile for Latus Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Latus Bio, we're pioneering novel treatments for CNS disorders using groundbreaking AAV capsids. Our capsid variants boast unparalleled potency, specificity, and trophism, each meticulously crafted with a particular disease in mind. By targeting precise brain regions and cell types, we aim to revolutionize the treatment landscape for conditions like CLN2 (Batten Disease) and Huntington’s Disease. Our focus isn't just on t...
At Latus Bio, we're pioneering novel treatments for CNS disorders using groundbreaking AAV capsids. Our capsid variants boast unparalleled potency, specificity, and trophism, each meticulously crafted with a particular disease in mind. By targeting precise brain regions and cell types, we aim to revolutionize the treatment landscape for conditions like CLN2 (Batten Disease) and Huntington’s Disease. Our focus isn't just on therapy development; it's on reshaping healthcare's future. We're committed to reducing therapeutic burden, improving safety, streamlining manufacturing, and broadening access, all while prioritizing patient well-being.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Philadelphia, PA
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251202268130/en/Latus-Bio-Announces-IND-Clearance-of-LTS-101-for-CLN2-Disease-and-Receipt-of-Fast-Track-Orphan-Drug-and-Rare-Pediatric-Disease-Designations

BUSINESSWIRE
02 Dec 2025

https://www.businesswire.com/news/home/20251103349850/en/Latus-Bio-Launches-AIML-Strategy-to-Transform-AAV-Gene-Therapy-Adds-Two-Leading-Experts-in-Peptide-and-Protein-Modeling-to-Scientific-Advisory-Board

BUSINESSWIRE
03 Nov 2025

https://www.businesswire.com/news/home/20250602421792/en/Latus-Bio-Strengthens-Executive-Team-with-Appointments-of-Ainslie-Little-as-COO-and-Katie-Hewitt-as-interim-CBO

BUSINESSWIRE
02 Jun 2025

https://www.businesswire.com/news/home/20250520133561/en/Latus-Bio-Announces-Publication-of-Breakthrough-Research-on-Novel-AAV-Capsid-Variant-for-Huntingtons-and-Parkinsons-Disease-Gene-Therapy

BUSINESSWIRE
20 May 2025

https://www.businesswire.com/news/home/20250514918759/en/Latus-Bio-Unveils-AAV-Ep-Capsid-Variant-Capable-of-Unprecedented-Protein-Production-in-the-Brain

BUSINESSWIRE
14 May 2025

https://www.businesswire.com/news/home/20250429582177/en/Latus-Bio-Announces-Multiple-Oral-and-Poster-Presentations-at-the-Upcoming-American-Society-for-Gene-and-Cell-Therapy-Annual-Meeting

BUSINESSWIRE
29 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty